Vienna - Delayed Quote EUR

Edwards Lifesciences Corporation (EWLS.VI)

63.12

+0.58

+(0.93%)

At close: April 16 at 5:32:14 PM GMT+2

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

IRVINE, Calif., April 16, 2025--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Business Wire 18 hours ago

EW
Edwards receives CE mark for Sapien M3 mitral valve replacement device

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s Mitraclip.

MedTech Dive 2 days ago

EW
Edwards secures CE mark for transfemoral mitral valve implant

Edwards’ mitral valve implant approval in Europe mounts a challenge to long-time market dominator Abbott.

Medical Device Network 2 days ago

EW

GLDAF
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

IRVINE, Calif., April 14, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company’s SAPIEN technology, the SAPIEN M3 system is the world's first approved transcatheter valve replacement therap

Business Wire 2 days ago

EW
Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, alongside data indicating the increased effectiveness of electronic notifications in treating severe aortic stenosis, comes amid broader market volatility. The past week saw a 1.58% rise in Edwards Lifesciences' stock, contrasting with a 3.4% drop in the overall market as concerns about tariffs...

Simply Wall St. 15 days ago

EW
Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S. companies that are leading the way in crucial areas of positive structural transformation within the economy. The fund returned 8.8% (net) in the fourth […]

Insider Monkey 15 days ago

EW
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

CHICAGO, March 31, 2025--Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease.

Business Wire 16 days ago

EW
Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now!

We recently published a list of Jim Cramer Put These 16 Stocks Under a Microscope. In this article, we are going to take a look at where Edwards Lifesciences (NYSE:EW) stands against other stocks that Jim Cramer put under a microscope. On Thursday, Jim Cramer, the host of Mad Money, shared his thoughts on the […]

Insider Monkey 16 days ago

EW

BSX
Medtronic’s Evolut trial outcome could shift US TAVR market

Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction than SAPIEN.

Medical Device Network 27 days ago

MDT

EW
Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group

We recently published an article titled Top 12 Stocks to Buy According to Citadel Investment Group. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against the other stocks. Citadel Investment Group was officially founded by Ken Griffin on November 1, 1990, with $4.2 million in assets under […]

Insider Monkey last month

EW
Edwards Lifesciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Edwards Lifesciences ( NYSE:EW ) Full Year 2024 Results Key Financial Results Revenue: US$5.44b (up 8.6% from FY 2023...

Simply Wall St. last month

EW
Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

IRVINE, Calif., February 25, 2025--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.

Business Wire last month

EW
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?

EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Zacks last month

EW
The three-year loss for Edwards Lifesciences (NYSE:EW) shareholders likely driven by its shrinking earnings

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. last month

EW
Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Investor's Business Daily 2 months ago

EW
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength

On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This represents a 9% year-over-year growth, supported by gains in all product groups. Adjusted earnings per share came in at 59 cents, compared to analysts’ estimate of 55 cents. Transcatheter Aortic Valve Replacement (TAVR) global sales grew 5.3% year-over-year to $1.04 billion in the fourth quarter. Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached

Benzinga 2 months ago

EW
Q4 2024 Edwards Lifesciences Corp Earnings Call

Q4 2024 Edwards Lifesciences Corp Earnings Call

Thomson Reuters StreetEvents 2 months ago

EW
Is Edwards Lifesciences Corporation (EW) the Best Medical Device Stock to Buy?

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other best medical device stocks to buy right now. Overview of the Medical Devices Sector According to a report […]

Insider Monkey 2 months ago

EW
Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...

Simply Wall St. 2 months ago

EW
Edwards predicts second-half lift from TAVR label expansion

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

MedTech Dive 2 months ago

EW

Performance Overview

Return	EWLS.VI	S&P 500 (^GSPC)
YTD	-13.09%	-10.30%
1-Year	-25.15%	+4.44%
3-Year	-43.50%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Edwards Lifesciences Corporation (EWLS.VI)

Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

Edwards receives CE mark for Sapien M3 mitral valve replacement device

Edwards secures CE mark for transfemoral mitral valve implant

Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System

Edwards Lifesciences (NYSE:EW) Presents Promising AS Treatment Data At ACC Session

Sands Capital Select Growth Fund Sold Edwards Lifesciences Corporation (EW) For Better Opportunities

New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients

Jim Cramer Calls Edwards Lifesciences (EW) a Hold – Prefers Boston Scientific Right Now!

Medtronic’s Evolut trial outcome could shift US TAVR market

Edwards Lifesciences Corporation (EW): Among the Top Stocks to Buy According to Citadel Investment Group

Edwards Lifesciences Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Edwards Lifesciences to Present at the TD Cowen 45th Annual Health Care Conference

Should Edwards Lifesciences Stock Remain in Your Portfolio Now?

The three-year loss for Edwards Lifesciences (NYSE:EW) shareholders likely driven by its shrinking earnings

Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength

Q4 2024 Edwards Lifesciences Corp Earnings Call

Is Edwards Lifesciences Corporation (EW) the Best Medical Device Stock to Buy?

Edwards Lifesciences (NYSE:EW) Is Reinvesting At Lower Rates Of Return

Edwards predicts second-half lift from TAVR label expansion

Performance Overview